There are an estimated 7.5 million patients suffering from psoriasis in the US. Approximately 85% of these patients are treated with topical creams and ointments that are of limited efficacy and burdened with side effects.
SDI-01 is a novel approach to treatment, not a steroid, with potentially greater and longer lasting efficacy. SDI-01 has blockbuster potential at modest development costs and timelines.